Vaso Corporation (VASO)

[ProfitScout]

Vasomedical to Hold First Quarter Fiscal 2006 Financial Results Conference Call on October 14, 2005

WESTBURY, N.Y., Oct 11, 2005 (BUSINESS WIRE) -- Vasomedical, Inc. (NASDAQ SmallCap: VASO), will report financial results for the first quarter of fiscal 2006 on Thursday, October 13, 2005 after market close and will hold a conference call on Friday, October 14, 2005 at 10:00 a.m. Eastern Time to discuss these results. Thomas Glover, president and chief executive officer, and Thomas W. Fry, chief financial officer, will host the conference call.

To participate in the live call by telephone, please dial [phone] from the U.S., or for international callers, please dial [phone]. A telephone replay will be available until 11:59 p.m. Eastern Time on October 16, 2005 by dialing [phone] from the U.S. or [phone] for international callers and entering passcode 1358470.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's web site at www.vasomedical.com. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install the necessary audio software. The call will be archived on the Company's web site for 30 days.

About Vasomedical, Inc.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's unique proprietary technology. EECP therapy is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of stable or unstable angina, congestive heart failure, acute myocardial infarction and cardiogenic shock. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP equipment, treatment guidance and a staff training and equipment maintenance program designed to provide optimal patient outcomes. Additional information is available on the Company's website at www.vasomedical.com. EECP is a registered trademark for Vasomedical's enhanced external counterpulsation systems.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipated," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

SOURCE: Vasomedical, Inc.

Vasomedical, Inc.
Thomas W. Fry, 516-997-4600
[e-mail]
or
Investor Relations:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
[e-mail]
Lisa Lindberg, 212-838-3777
[e-mail]
Bruce Voss, 310-691-7100
[e-mail]


Copyright Business Wire 2005